

Editorial

Welcome to *Seminars in Thrombosis & Hemostasis* 2016: New (2014) Impact Factor and Most Highly Cited Articles

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia

Semin Thromb Hemost 2016;42:1–4.

Welcome to the start of yet another year with *Seminars in Thrombosis & Hemostasis* (STH). This is my 8th year as the Editor-in-Chief, and my 11th year of editorial association with this journal, having originally served as a Regional Editor. First, I sincerely wish to thank all the contributors to STH over the past years, as well as the Guest Editors for these issues, and of course the current and past Senior and Associate Editors of the journal. There have been several changes to the editorial team. We have two new Senior Editors: Ton Lisman joins Marcel Levi as a second European Senior Editor, and Sam Schulman, a long-time Associate Editor of STH, joins Hau Kwaan as a second North American Senior Editor. We have also increased the ranks of Associate Editors, with the aim to have around 10 to 12 contributing issues from each of the “global regions” of America, Europe, and Asia-Pacific.

I will also take this opportunity to thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal. In particular, I would like to thank Subhankar De, the Production Editor for STH who now leads the production team. I also wish to thank Kelly Coffey, a Journals Coordinator for Thieme Medical Publishers, as well as other key people at Thieme, some of whom prefer to remain unnamed, for the additional support provided over recent years.

This is also the time that we reflect on our journal's impact factor, which for 2014 was 3.876, which represents a small rise from our 2013 impact factor of 3.693 (► **Fig. 1**). I am hopeful that this reflects a stabilization of the STH impact factor at around 4 over the coming years. In any case, the impact factor is not the only marker of journal “quality” that we should consider, given the existence of other biometric markers and the limitations of any individual marker (including the impact factor) as a “quality” indicator.^{1,2}

As I also now do annually, the highest cited (2012/2013-published) contributions^{3–43} from this journal are listed

in ► **Table 1** for the potential interest of the readership and contributing authors. These contributions identify those publications, most contributing to the 2014 impact factor, and each have now been cited 15 or more times in literature, with the top 11-listed articles having been cited 25 or more times. For those interested, the current listing can be compared with those of the most recently published top downloaded article listings from STH, the basis of the Eberhard F. Mammen “most popular” awards.^{44,45} Accordingly, I would like to thank all the contributors, guest editors, and the editorial team for bringing us the content that makes STH.

Finally, a short note to confirm that, as always, we will continue to develop plans for the future content of this journal, and we are confident that we will be able to continue to bring its readers the high-quality journal that is expected from us. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in ► **Table 2**.




Fig. 1 The impact factor for *Seminars in Thrombosis & Hemostasis*, from 2003 to 2014.

Address for correspondence
Dr. E. J. Favaloro, FFSc (RCPA),
Department of Haematology,
Institute of Clinical Pathology and
Medical Research (ICPMR),
Westmead Hospital, Westmead,
NSW 2145, Australia
(e-mail: emmanuel.
favaloro@health.nsw.gov.au).

Issue Theme Editorial
Compilation I; Guest Editors:
Emmanuel J. Favaloro, PhD, FFSc
(RCPA), and Giuseppe Lippi, MD.

Copyright © 2016 by Thieme Medical
Publishers, Inc., 333 Seventh Avenue,
New York, NY 10001, USA.
Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0035-1568874>.
ISSN 0094-6176.

Table 1 Most highly cited, 2012/2013 published, contributions from *Seminars in Thrombosis & Hemostasis*

1 Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. <i>Semin Thromb Hemost</i> 2012;38(6):565–575
2 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. <i>Semin Thromb Hemost</i> 2012;38(1):16–22
3 Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. <i>Semin Thromb Hemost</i> 2012;38(2):178–184
4 Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. <i>Semin Thromb Hemost</i> 2012;38(5):535–548
5 Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2012;38(4):305–321
6 Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. <i>Semin Thromb Hemost</i> 2012;38(6):576–585
7 Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? <i>Semin Thromb Hemost</i> 2012;38(4):322–327
8 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. <i>Semin Thromb Hemost</i> 2012;38(1):79–94
9 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. <i>Semin Thromb Hemost</i> 2012;38(1):102–113
10 Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. <i>Semin Thromb Hemost</i> . 2012 Mar;38(2):200–12.
11 Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. <i>Semin Thromb Hemost</i> 2012;38(4):375–384
12 Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. <i>Semin Thromb Hemost</i> 2013;39(4):356–364
13 Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. <i>Semin Thromb Hemost</i> 2013;39(3):258–266
14 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. <i>Semin Thromb Hemost</i> 2013;39(5):559–566
15 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. <i>Semin Thromb Hemost</i> 2012;38(7):673–682
16 Plebani M, Favaloro EJ, Lippi G. Patient safety and quality in laboratory and hemostasis testing: a renewed loop? <i>Semin Thromb Hemost</i> 2012;38(6):553–558
17 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. <i>Semin Thromb Hemost</i> 2012;38(4):404–411
18 Sørensen B, Larsen OH, Rea CJ, Tang M, Foley JH, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. <i>Semin Thromb Hemost</i> 2012;38(3):268–273
19 Franchini M, Coppola A, Rocino A, et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. <i>Semin Thromb Hemost</i> 2013;39(7):752–766
20 Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti-β ₂ -glycoprotein I antibodies. <i>Semin Thromb Hemost</i> 2012;38(4):390–403
21 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. <i>Semin Thromb Hemost</i> 2012;38(5):454–462
22 Harenberg J, Du S, Krämer S, et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. <i>Semin Thromb Hemost</i> 2013;39(1):66–71
23 Tufano A, Di Capua M, Coppola A, et al. The infectious burden in atherothrombosis. <i>Semin Thromb Hemost</i> 2012;38(5):515–523
24 Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. <i>Semin Thromb Hemost</i> 2012;38(4):385–389
25 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. <i>Semin Thromb Hemost</i> 2012;38(1):47–54
26 Salmela B, Jouts-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30
27 Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. <i>Semin Thromb Hemost</i> 2012;38(5):447–453

Table 1 (Continued)

28 Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: more than skin deep. <i>Semin Thromb Hemost</i> 2012;38(1):114–124
29 Favaloro EJ, Plebani M, Lippi G. Regulation in hemostasis and thrombosis: part I-in vitro diagnostics. <i>Semin Thromb Hemost</i> 2013;39(3):235–249
30 Turner N, Nolasco L, Moake J. Generation and breakdown of soluble ultralarge von Willebrand factor multimers. <i>Semin Thromb Hemost</i> 2012;38(1):38–46
31 Duga S, Salomon O. Congenital factor XI deficiency: an update. <i>Semin Thromb Hemost</i> 2013;39(6):621–631
32 Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. <i>Semin Thromb Hemost</i> 2013;39(2):214–228
33 Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. <i>Semin Thromb Hemost</i> 2012;38(7):742–752
34 Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. <i>Semin Thromb Hemost</i> 2012;38(4):333–338
35 Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. <i>Semin Thromb Hemost</i> 2013;39(4):382–391
36 Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. <i>Semin Thromb Hemost</i> 2012;38(5):506–514
37 Franchini M, Mannucci PM. Thrombin and cancer: from molecular basis to therapeutic implications. <i>Semin Thromb Hemost</i> 2012;38(1):95–101
38 Di Minno MN, Iervolino S, Lupoli R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. <i>Semin Thromb Hemost</i> 2012;38(5):497–505
39 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. <i>Semin Thromb Hemost</i> 2012;38(5):483–496
40 Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. <i>Semin Thromb Hemost</i> 2012;38(4):360–374

Table 2 The current planned topics for future issues of *Seminars in Thrombosis & Hemostasis* include

<ul style="list-style-type: none"> • Editorial compilations (continuing series) • At the crossroads of transfusion medicine and hemostasis • Platelet function in thrombosis and hemostasis • Controversies in inherited bleeding disorders • The role of fibrinogen and factor XIII in hemostasis, and the identification and treatment of associated disorders • Thrombosis & hemostasis in women and during pregnancy • Laboratory assessment and monitoring of therapy in thrombosis and bleeding disorders • Fibrinolysis • Antiphospholipid antibodies and the antiphospholipid syndrome

At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises. We look forward to another interesting year of reading in 2016.

References

- 1 Favaloro EJ. The journal impact factor: don't expect its demise any time soon. *Clin Chem Lab Med* 2009;47(11):1319–1324
- 2 Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. *Semin Thromb Hemost* 2008;34(1):7–25
- 3 Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. *Semin Thromb Hemost* 2012;38(6):565–575
- 4 Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. *Semin Thromb Hemost* 2012; 38(1):16–22
- 5 Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. *Semin Thromb Hemost* 2012; 38(2):178–184
- 6 Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. *Semin Thromb Hemost* 2012;38(5): 535–548
- 7 Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. *Semin Thromb Hemost* 2012;38(4):305–321

- 8 Adcock Funk DM, Lippi G, Favalaro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. *Semin Thromb Hemost* 2012;38(6):576–585
- 9 Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? *Semin Thromb Hemost* 2012;38(4):322–327
- 10 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. *Semin Thromb Hemost* 2012;38(1):79–94
- 11 Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. *Semin Thromb Hemost* 2012;38(1):102–113
- 12 Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. *Semin Thromb Hemost* 2012;38(2):200–212
- 13 Coppola A, Favalaro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I—acquired hemophilia A. *Semin Thromb Hemost* 2012;38(5):433–446
- 14 Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. *Semin Thromb Hemost* 2012;38(4):375–384
- 15 Declercq PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. *Semin Thromb Hemost* 2013;39(4):356–364
- 16 Lippi G, Plebani M, Favalaro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. *Semin Thromb Hemost* 2013;39(3):258–266
- 17 Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. *Semin Thromb Hemost* 2013;39(5):559–566
- 18 Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. *Semin Thromb Hemost* 2012;38(7):673–682
- 19 Plebani M, Favalaro EJ, Lippi G. Patient safety and quality in laboratory and hemostasis testing: a renewed loop? *Semin Thromb Hemost* 2012;38(6):553–558
- 20 Favalaro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. *Semin Thromb Hemost* 2012;38(4):404–411
- 21 Sørensen B, Larsen OH, Rea CJ, Tang M, Foley JH, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. *Semin Thromb Hemost* 2012;38(3):268–273
- 22 Franchini M, Coppola A, Rocino A, et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. *Semin Thromb Hemost* 2013;39(7):752–766
- 23 Favalaro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti- β 2-glycoprotein I antibodies. *Semin Thromb Hemost* 2012;38(4):390–403
- 24 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. *Semin Thromb Hemost* 2012;38(5):454–462
- 25 Harenberg J, Du S, Krämer S, et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. *Semin Thromb Hemost* 2013;39(1):66–71
- 26 Tufano A, Di Capua M, Coppola A, et al. The infectious burden in atherothrombosis. *Semin Thromb Hemost* 2012;38(5):515–523
- 27 Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. *Semin Thromb Hemost* 2012;38(4):385–389
- 28 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(1):47–54
- 29 Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. *Semin Thromb Hemost* 2012;38(1):23–30
- 30 Franchini M, Lippi G, Favalaro EJ. Acquired inhibitors of coagulation factors: part II. *Semin Thromb Hemost* 2012;38(5):447–453
- 31 Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: more than skin deep. *Semin Thromb Hemost* 2012;38(1):114–124
- 32 Favalaro EJ, Plebani M, Lippi G. Regulation in hemostasis and thrombosis: part I—in vitro diagnostics. *Semin Thromb Hemost* 2013;39(3):235–249
- 33 Turner N, Nolasco L, Moake J. Generation and breakdown of soluble ultralarge von Willebrand factor multimers. *Semin Thromb Hemost* 2012;38(1):38–46
- 34 Duga S, Salomon O. Congenital factor XI deficiency: an update. *Semin Thromb Hemost* 2013;39(6):621–631
- 35 Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. *Semin Thromb Hemost* 2013;39(2):214–228
- 36 Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. *Semin Thromb Hemost* 2012;38(7):742–752
- 37 Cervera R, Espinosa G. Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry”. *Semin Thromb Hemost* 2012;38(4):333–338
- 38 Kwaan HC, Mazar AP, McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. *Semin Thromb Hemost* 2013;39(4):382–391
- 39 Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. *Semin Thromb Hemost* 2012;38(5):506–514
- 40 Franchini M, Mannucci PM. Thrombin and cancer: from molecular basis to therapeutic implications. *Semin Thromb Hemost* 2012;38(1):95–101
- 41 Di Minno MN, Iervolino S, Lupoli R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. *Semin Thromb Hemost* 2012;38(5):497–505
- 42 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. *Semin Thromb Hemost* 2012;38(5):483–496
- 43 Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. *Semin Thromb Hemost* 2012;38(4):360–374
- 44 Favalaro EJ. 2014 Eberhard F. Mammen Award announcements: Part I—Most popular articles. *Semin Thromb Hemost* 2014;40(4):407–412
- 45 Favalaro EJ. 2015 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles. *Semin Thromb Hemost* 2015;41(7):673–679